Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas

ZAMBO, Iva, Markéta HERMANOVÁ, Danica ZAPLETALOVÁ, Jan ŠKODA, Peter MÚDRY, Michal KÝR, Karel ZITTERBART, Jaroslav ŠTĚRBA and Renata VESELSKÁ. Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas. Cancer Biomarkers. Amsterdam: IOS Press, 2016, vol. 17, No 1, p. 107-116. ISSN 1574-0153. Available from: https://dx.doi.org/10.3233/CBM-160623.

Basic information

• Original name: Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas
• Authors: ZAMBO, Iva (203 Czech Republic, belonging to the institution), Markéta HERMANOVÁ (203 Czech Republic, belonging to the institution), Danica ZAPLETALOVÁ (703 Slovakia, belonging to the institution), Jan ŠKODA (203 Czech Republic, belonging to the institution), Peter MÚDRY (203 Czech Republic, belonging to the institution), Michal KÝR (203 Czech Republic, belonging to the institution), Karel ZITTERBART (203 Czech Republic, belonging to the institution), Jaroslav ŠTĚRBA (203 Czech Republic, belonging to the institution) and Renata VESELSKÁ (203 Czech Republic, guarantor, belonging to the institution).
• Edition: Cancer Biomarkers, Amsterdam, IOS Press, 2016, 1574-0153.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30209 Paediatrics
• Country of publisher: Netherlands
• Confidentiality degree: is not subject to a state or trade secret
• Impact factor: Impact factor: 2.274
• RIV identification code: RIV/00216224:14310/16:00088884
• Organization unit: Faculty of Science
• Doi: http://dx.doi.org/10.3233/CBM-160623
• UT WoS: 000381114300014
• Keywords in English: rhabdomyosarcoma;Ewing sarcoma;osteosarcoma;cancer stem cell markers;prognosis
• Tags: AKR, EL OK, podil, rivok
• Tags: International impact, Reviewed

Abstract

Nestin, CD133 and ABCG2 are recently discussed as putative markers, co-expression of which might determine a cancer stem cell (CSC) phenotype in sarcomas. Our study is focused on immunohistochemical analysis of nestin, CD133 and ABCG2 expression in rhabdomyosarcoma, Ewing sarcoma and osteosarcoma. Furthermore, we also analyzed the possible correlation of nestin, CD133 and ABCG2 expression levels with the patient outcome to identify potential prognostic values of these three putative CSC markers in the same cohorts. Using immunohistochemistry, expression of nestin, CD133 and ABCG2 was analyzed in 24 rhabdomyosarcoma, 22 Ewing sarcoma and 10 osteosarcoma tissue samples and expression levels of these markers were correlated with clinical outcome. High nestin levels indicate poor prognosis in patients with Ewing sarcoma (P = 0.001), and high CD133 expression is associated with shorter survival in rhabdomyosarcoma patients (P = 0.002). In contrast, no significant relationship was found between ABCG2 expression and the clinical outcome. Our analysis represents the first complex study of these three putative CSCs markers together in three different types of pediatric sarcomas and showed their possible prognostic values in these tumors.

Links

• NT13443, research and development project: Name: Identifikace a charakterizace nádorových kmenových buněk u sarkomů dětského věku.